Login to Your Account



Financings Roundup

Pluristem's PLX-PAD Plans Boosted by $36M Offering

By Jennifer Boggs


Friday, January 28, 2011
A week after disclosing plans for an upcoming Phase II/III trial of placenta-derived cell therapy PLX-PAD in critical limb ischemia (CLI), Pluristem Therapeutics Inc. is securing some much-needed funding in a public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription